148 related articles for article (PubMed ID: 24697167)
1. Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation.
Aditya N; Ravi PR; Avula US; Vats R
J Microencapsul; 2014; 31(5):508-18. PubMed ID: 24697167
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism.
Ravi PR; Aditya N; Kathuria H; Malekar S; Vats R
Eur J Pharm Biopharm; 2014 May; 87(1):114-24. PubMed ID: 24378615
[TBL] [Abstract][Full Text] [Related]
3. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
4. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
Du X; Gao N; Song X
Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
[TBL] [Abstract][Full Text] [Related]
5. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
Ahmed OA; Badr-Eldin SM
Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
[TBL] [Abstract][Full Text] [Related]
6. Preparation and evaluation of raloxifene-loaded solid dispersion nanoparticle by spray-drying technique without an organic solvent.
Tran TH; Poudel BK; Marasini N; Chi SC; Choi HG; Yong CS; Kim JO
Int J Pharm; 2013 Feb; 443(1-2):50-7. PubMed ID: 23318367
[TBL] [Abstract][Full Text] [Related]
7. Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.
Tshweu L; Katata L; Kalombo L; Chiappetta DA; Hocht C; Sosnik A; Swai H
Nanomedicine (Lond); 2014; 9(12):1821-33. PubMed ID: 24364871
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin.
Wempe MF; Wacher VJ; Ruble KM; Ramsey MG; Edgar KJ; Buchanan NL; Buchanan CM
Int J Pharm; 2008 Jan; 346(1-2):25-37. PubMed ID: 17644287
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
10. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
Gupta T; Kenjale P; Pokharkar V
Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
[TBL] [Abstract][Full Text] [Related]
11. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics.
Kanade R; Boche M; Pokharkar V
AAPS PharmSciTech; 2018 Apr; 19(3):1105-1115. PubMed ID: 29181706
[TBL] [Abstract][Full Text] [Related]
12. Enhanced bioavailability of raloxifene hydrochloride via dry suspensions prepared from drug/HP-β-cyclodextrin inclusion complexes.
Lu R; Liu S; Wang Q; Li X
Pharmazie; 2015 Dec; 70(12):791-7. PubMed ID: 26817276
[TBL] [Abstract][Full Text] [Related]
13. Proliposome powders for enhanced intestinal absorption and bioavailability of raloxifene hydrochloride: effect of surface charge.
Velpula A; Jukanti R; Janga KY; Sunkavalli S; Bandari S; Kandadi P; Veerareddy PR
Drug Dev Ind Pharm; 2013 Dec; 39(12):1895-906. PubMed ID: 22458264
[TBL] [Abstract][Full Text] [Related]
14. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.
Stovall DW; Utian WH; Gass ML; Qu Y; Muram D; Wong M; Plouffe L
Menopause; 2007; 14(3 Pt 1):510-7. PubMed ID: 17314736
[TBL] [Abstract][Full Text] [Related]
15. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
16. [Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats].
Gao H; Xi S; Xu L
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):935-8. PubMed ID: 24495689
[TBL] [Abstract][Full Text] [Related]
17. Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique.
Tran TH; Poudel BK; Marasini N; Woo JS; Choi HG; Yong CS; Kim JO
Arch Pharm Res; 2013 Jan; 36(1):86-93. PubMed ID: 23325488
[TBL] [Abstract][Full Text] [Related]
18. Colon-targeted celecoxib-loaded Eudragit® S100-coated poly-ε-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats.
Ghorab DM; Amin MM; Khowessah OM; Tadros MI
Drug Deliv; 2011; 18(7):523-35. PubMed ID: 21793779
[TBL] [Abstract][Full Text] [Related]
19. The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method.
Nabi-Meibodi M; Vatanara A; Najafabadi AR; Rouini MR; Ramezani V; Gilani K; Etemadzadeh SM; Azadmanesh K
Colloids Surf B Biointerfaces; 2013 Dec; 112():408-14. PubMed ID: 24036624
[TBL] [Abstract][Full Text] [Related]
20. Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation.
Mahmood S; Mandal UK; Chatterjee B
Int J Pharm; 2018 May; 542(1-2):36-46. PubMed ID: 29501737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
